These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 25158280)
1. MEIS1 functions as a potential AR negative regulator. Cui L; Li M; Feng F; Yang Y; Hang X; Cui J; Gao J Exp Cell Res; 2014 Oct; 328(1):58-68. PubMed ID: 25158280 [TBL] [Abstract][Full Text] [Related]
2. LINE-1 ORF-1p functions as a novel androgen receptor co-activator and promotes the growth of human prostatic carcinoma cells. Lu Y; Feng F; Yang Y; Gao X; Cui J; Zhang C; Zhang F; Xu Z; Qv J; Wang C; Zeng Z; Zhu Y; Yang Y Cell Signal; 2013 Feb; 25(2):479-89. PubMed ID: 23153584 [TBL] [Abstract][Full Text] [Related]
3. MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity. Whitlock NC; Trostel SY; Wilkinson S; Terrigino NT; Hennigan ST; Lake R; Carrabba NV; Atway R; Walton ED; Gryder BE; Capaldo BJ; Ye H; Sowalsky AG Oncogene; 2020 Aug; 39(34):5663-5674. PubMed ID: 32681068 [TBL] [Abstract][Full Text] [Related]
4. Regulation of androgen receptor-mediated transcription by RPB5 binding protein URI/RMP. Mita P; Savas JN; Djouder N; Yates JR; Ha S; Ruoff R; Schafler ED; Nwachukwu JC; Tanese N; Cowan NJ; Zavadil J; Garabedian MJ; Logan SK Mol Cell Biol; 2011 Sep; 31(17):3639-52. PubMed ID: 21730289 [TBL] [Abstract][Full Text] [Related]
5. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer. Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058 [TBL] [Abstract][Full Text] [Related]
6. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage. Li L; Xie H; Liang L; Gao Y; Zhang D; Fang L; Lee SO; Luo J; Chen X; Wang X; Chang LS; Yeh S; Wang Y; He D; Chang C Carcinogenesis; 2013 Feb; 34(2):257-67. PubMed ID: 23104178 [TBL] [Abstract][Full Text] [Related]
7. Purification and identification of a novel complex which is involved in androgen receptor-dependent transcription. Hosohata K; Li P; Hosohata Y; Qin J; Roeder RG; Wang Z Mol Cell Biol; 2003 Oct; 23(19):7019-29. PubMed ID: 12972618 [TBL] [Abstract][Full Text] [Related]
8. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor. Yoon HG; Wong J Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395 [TBL] [Abstract][Full Text] [Related]
9. Tumor suppressor PAX6 functions as androgen receptor co-repressor to inhibit prostate cancer growth. Shyr CR; Tsai MY; Yeh S; Kang HY; Chang YC; Wong PL; Huang CC; Huang KE; Chang C Prostate; 2010 Feb; 70(2):190-9. PubMed ID: 19790232 [TBL] [Abstract][Full Text] [Related]
10. Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells. Tsui KH; Chang YL; Feng TH; Hou CP; Lin YH; Yang PS; Lee BW; Juang HH Prostate; 2018 Mar; 78(4):242-249. PubMed ID: 29164633 [TBL] [Abstract][Full Text] [Related]
11. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1. Zaia A; Fraizer GC; Piantanelli L; Saunders GF Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720 [TBL] [Abstract][Full Text] [Related]
12. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes. Axlund SD; Lambert JR; Nordeen SK Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772 [TBL] [Abstract][Full Text] [Related]
13. Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors. Li N; Chen M; Truong S; Yan C; Buttyan R Prostate; 2014 Oct; 74(14):1400-10. PubMed ID: 25132524 [TBL] [Abstract][Full Text] [Related]
14. Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells. Cinar B; Yeung F; Konaka H; Mayo MW; Freeman MR; Zhau HE; Chung LW Biochem J; 2004 Apr; 379(Pt 2):421-31. PubMed ID: 14715080 [TBL] [Abstract][Full Text] [Related]
15. Hypoxia increases androgen receptor activity in prostate cancer cells. Park SY; Kim YJ; Gao AC; Mohler JL; Onate SA; Hidalgo AA; Ip C; Park EM; Yoon SY; Park YM Cancer Res; 2006 May; 66(10):5121-9. PubMed ID: 16707435 [TBL] [Abstract][Full Text] [Related]
17. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells. Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946 [TBL] [Abstract][Full Text] [Related]
18. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells. Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046 [TBL] [Abstract][Full Text] [Related]
19. Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3. Argiropoulos B; Yung E; Xiang P; Lo CY; Kuchenbauer F; Palmqvist L; Reindl C; Heuser M; Sekulovic S; Rosten P; Muranyi A; Goh SL; Featherstone M; Humphries RK Blood; 2010 May; 115(20):4071-82. PubMed ID: 20237320 [TBL] [Abstract][Full Text] [Related]
20. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]